NeuroSense Therapeutics Ltd. (NRSNW) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
NeuroSense Therapeutics Ltd. (NRSNW) trades at $0.05 with AI Score 42/100 (Grade C). NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. Market cap: $1.23M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for NRSNW: NRSNW does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NRSNW against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
NRSNW: the 3 scored disciplines are evenly split. Dominant signal: Ken Griffin bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
NeuroSense Therapeutics Ltd. (NRSNW) Healthcare & Pipeline Overview
NeuroSense Therapeutics Ltd., an Israeli clinical-stage biotechnology firm, pioneers treatments for neurodegenerative diseases, primarily focusing on ALS with its lead candidate PrimeC. The company operates in a competitive biotech landscape, emphasizing novel oral formulations to address unmet medical needs in neurodegenerative disorders.
What Is the Investment Thesis for NRSNW?
NeuroSense Therapeutics presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's valuation is currently tied to the clinical progress of PrimeC, its lead candidate for ALS, and the advancement of its preclinical assets, StabiliC and CogniC. Successful clinical trials for PrimeC could serve as a significant value driver, addressing a critical unmet need in ALS treatment. However, the company's financial viability depends on securing additional funding, given its current market capitalization of $1.23M and negative P/E ratio of -2.40. Investors should closely monitor clinical trial outcomes, regulatory milestones, and the company's ability to secure partnerships or funding to mitigate risks associated with biotechnology investments. Beta is 1.61.
Based on FMP financials and quantitative analysis
NRSNW Key Highlights
NeuroSense Therapeutics focuses on developing treatments for neurodegenerative diseases, including ALS, Parkinson's, and Alzheimer's.
- Lead product candidate, PrimeC, is a novel oral formulation for ALS treatment.
- Preclinical pipeline includes StabiliC for Parkinson's disease and CogniC for Alzheimer's disease.
- The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
- The company has a market capitalization of $1.23M and a P/E ratio of -2.40.
Who Are NRSNW's Competitors?
NRSNW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ACXP Acurx Pharmaceuticals, Inc. | $1.45 | +0.69% | $6.23M | 30 |
| ADIL Adial Pharmaceuticals, Inc. | $5.90 | +2.52% | $5.66M | 31 |
| ADXN Addex Therapeutics Ltd | $4.57 | -19.82% | $5.63M | 44 |
| APRE Aprea Therapeutics, Inc. | $0.64 | -4.62% | $7.92M | 30 |
| BCLI Brainstorm Cell Therapeutics Inc. | $1.06 | -12.94% | $11.7M | 63 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NRSNW's Key Strengths?
Focus on neurodegenerative diseases with high unmet needs.
- Novel oral formulation for ALS treatment (PrimeC).
- Preclinical pipeline targeting Parkinson's and Alzheimer's diseases.
- Experienced management team in biotechnology development.
What Are NRSNW's Weaknesses?
Limited financial resources and market capitalization.
- Dependence on successful clinical trials for PrimeC.
- Early stage of development for preclinical assets.
- Competition from larger, more established biotechnology companies.
What Could Drive NRSNW Stock Higher?
Announcement of Phase 2b clinical trial results for PrimeC in ALS patients.
- Progression of StabiliC for Parkinson's disease into Phase 1 clinical trials.
- Advancement of CogniC for Alzheimer's disease through preclinical studies.
What Are the Key Risks for NRSNW?
Failure to secure additional funding to support ongoing clinical trials and research activities.
- Unfavorable clinical trial results for PrimeC or other product candidates.
- Regulatory delays or rejection of marketing applications.
- Competition from other companies developing treatments for neurodegenerative diseases.
What Are the Growth Opportunities for NRSNW?
- Expansion of PrimeC Clinical Trials: NeuroSense has the opportunity to expand its clinical trials for PrimeC to include a broader patient population or to explore its efficacy in combination therapies. Successful trials could lead to accelerated regulatory approval and market adoption.
- Advancement of Preclinical Pipeline: NeuroSense can drive growth by advancing its preclinical assets, StabiliC for Parkinson's disease and CogniC for Alzheimer's disease, into clinical development. Positive preclinical data and successful Phase 1 trials could attract partnerships and funding, further validating the company's technology platform. The markets for Parkinson's and Alzheimer's treatments are substantial and growing, presenting significant long-term growth potential.
- Strategic Partnerships and Collaborations: NeuroSense can leverage strategic partnerships with larger pharmaceutical companies or research institutions to accelerate the development and commercialization of its product candidates. Collaborations can provide access to additional funding, expertise, and resources, enhancing the company's ability to navigate the complex regulatory landscape and bring new therapies to market more efficiently. This can also help to reduce the financial burden on the company.
- Geographic Expansion: NeuroSense has the opportunity to expand its geographic reach beyond Israel, targeting key markets in North America, Europe, and Asia. Entering new markets can increase the company's revenue potential and diversify its risk profile. However, geographic expansion requires careful planning and execution, including navigating regulatory requirements and establishing distribution networks.
- Orphan Drug Designation and Regulatory Pathways: NeuroSense can pursue orphan drug designation for its product candidates, which can provide regulatory and financial incentives, including market exclusivity and reduced development costs. Leveraging expedited regulatory pathways, such as fast track designation or breakthrough therapy designation, can also accelerate the approval process and bring new therapies to patients more quickly. These pathways can significantly enhance the company's competitive advantage.
What Threats Does NRSNW Face?
- Clinical trial failures or delays.
- Regulatory hurdles and approval timelines.
- Competition from existing and emerging therapies.
- Funding constraints and market volatility.
What Are NRSNW's Competitive Advantages?
- Proprietary drug formulations and delivery technologies.
- Patent protection for key product candidates.
- Clinical data demonstrating efficacy and safety.
- Expertise in neurodegenerative disease research and development.
What Does NRSNW Do?
NeuroSense Therapeutics Ltd., established in 2017 and headquartered in Herzliya, Israel, is a clinical-stage biotechnology company dedicated to the discovery and development of treatments for debilitating neurodegenerative diseases. The company's primary focus is on addressing conditions with significant unmet medical needs, such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, and Alzheimer's disease. NeuroSense's lead product candidate, PrimeC, is a novel oral formulation designed for the treatment of ALS. This drug aims to improve patient outcomes by targeting key mechanisms involved in the progression of the disease. In addition to PrimeC, NeuroSense has a preclinical pipeline that includes StabiliC for Parkinson's disease and CogniC for Alzheimer's disease, both of which are in the early stages of development. The company's strategy involves leveraging innovative scientific approaches and collaborations to advance its pipeline and bring new therapies to patients suffering from these devastating conditions. With a team of 17 employees, NeuroSense is committed to making a meaningful impact in the field of neurodegenerative disease treatment.
What Products and Services Does NRSNW Offer?
- Develop treatments for neurodegenerative diseases.
- Focus on amyotrophic lateral sclerosis (ALS), Parkinson's disease, and Alzheimer's disease.
- Develop novel oral formulations for drug delivery.
- Conduct preclinical and clinical trials to evaluate drug efficacy and safety.
- Seek regulatory approvals for new therapies.
- Explore strategic partnerships for research and development.
How Does NRSNW Make Money?
- Develop and patent novel drug formulations.
- Conduct clinical trials to demonstrate efficacy and safety.
- Seek regulatory approval from health authorities.
- Commercialize approved therapies through partnerships or direct sales.
What Industry Does NRSNW Operate In?
NeuroSense Therapeutics operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential for successful therapies. The company focuses on neurodegenerative diseases, a sector with a growing prevalence due to aging populations. Key competitors include companies like ACXP, ADIL, ADXN, APRE, and BCLI, all vying to develop innovative treatments for similar conditions. The market for neurodegenerative disease treatments is projected to grow substantially, driven by increasing diagnosis rates and the demand for more effective therapies.
Who Are NRSNW's Key Customers?
- Patients suffering from neurodegenerative diseases.
- Healthcare providers who treat these patients.
- Pharmaceutical companies seeking to license or acquire new therapies.
- Research institutions involved in neurodegenerative disease research.
Company Profile
NeuroSense Therapeutics Ltd. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Herzliya, IL. The company is led by CEO Alon Ben-Noon. NRSNW has traded publicly since 2021.
How NeuroSense Therapeutics Ltd. Is Valued
NeuroSense Therapeutics Ltd. carries a market capitalization of $1.23M, placing it in the micro-cap category. Relative to its peer group, NRSNW's quantitative score of 42/100 is roughly in line with the peer average of 40/100.
Key Financial Metrics
Its free cash flow yield is -26.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.31 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -109.4%, the inverse of the P/E and a quick read on earnings relative to price.
Forward Outlook
Wall Street analysts project NeuroSense Therapeutics Ltd. revenue of about $714K for fiscal 2026, with EPS near $-0.42. The estimate reflects 3 contributing analysts.
NRSNW Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that those closest to the business believe in its potential.
- Community sentiment has shifted positively, with discussions highlighting the innovative approaches NeuroSense is taking in neurodegenerative disease treatments.
- Recent partnerships with research institutions have bolstered credibility, enhancing the company's visibility and potential for breakthroughs.
- The growing interest in mental health and neurological therapies aligns with NeuroSense's focus, positioning it well within a trending market.
Bear Case
- Market perception remains cautious, with some investors concerned about the competitive landscape in the biotech sector, which can be volatile.
- Recent clinical trial results have faced scrutiny, leading to skepticism about the efficacy of NeuroSense's treatments among some community members.
- The lack of significant news or developments in the last month has led to a stagnant sentiment, causing some investors to reconsider their positions.
- Broader economic uncertainties may contribute to hesitance in investing in biotech firms, especially those still in developmental stages like NeuroSense.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
NRSNW Latest News
No recent news available for NRSNW.
NRSNW Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NRSNW.
Price Targets
Wall Street price target analysis for NRSNW.
NRSNW MoonshotScore
What does this score mean?
The MoonshotScore rates NRSNW 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Alon Ben-Noon
CEO
Alon Ben-Noon serves as the CEO of NeuroSense Therapeutics, bringing extensive experience in the biotechnology and pharmaceutical industries. His background includes a strong foundation in business development, strategic planning, and financial management. Prior to joining NeuroSense, Alon held leadership positions at various healthcare companies, where he was responsible for driving growth, securing funding, and managing strategic partnerships. His expertise spans across drug development, clinical trials, and commercialization strategies.
Track Record: Under Alon Ben-Noon's leadership, NeuroSense Therapeutics has focused on advancing its lead product candidate, PrimeC, through clinical trials for ALS treatment. He has overseen the expansion of the company's preclinical pipeline and has been instrumental in securing funding to support research and development activities. Alon has also focused on building strategic relationships with key stakeholders in the biotechnology industry.
Common Questions About NRSNW (Healthcare)
What does the AI Score mean for NRSNW?
NRSNW holds an AI Score of 42/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. Their lead product, PrimeC, targets amyotrophic lateral …
What does NeuroSense Therapeutics Ltd. do?
NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson's disease, and Alzheimer's disease. The company's lead product candidate, PrimeC, is a novel oral formulation designed for the treatment of ALS. NeuroSense also has a preclinical pipeline that includes StabiliC for Parkinson's disease and CogniC for Alzheimer's disease.
What are the main risks for NRSNW?
NeuroSense Therapeutics faces several risks, including the potential for clinical trial failures, regulatory delays, and competition from other companies developing treatments for neurodegenerative diseases. The company's financial viability depends on securing additional funding to support its research and development activities. Market volatility and changes in the biotechnology industry can also impact the company's stock price. Investors should carefully consider these risks before investing in NRSNW.
What are the key factors to evaluate for NRSNW?
NeuroSense Therapeutics Ltd. (NRSNW) holds an AI score of 42/100 (low). NeuroSense Therapeutics presents a high-risk, high-reward investment opportunity within the biotechnology sector. Not financial advice.
How frequently does NRSNW data refresh on this page?
NRSNW's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven NRSNW's recent stock price performance?
NeuroSense Therapeutics Ltd. (NRSNW) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on neurodegenerative diseases with high unmet needs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NRSNW overvalued or undervalued right now?
NeuroSense Therapeutics Ltd. (NRSNW) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research NRSNW before investing?
Before investing in NeuroSense Therapeutics Ltd. (NRSNW), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding NRSNW to a portfolio?
Key strength of NeuroSense Therapeutics Ltd. (NRSNW): Focus on neurodegenerative diseases with high unmet needs. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company data and may be subject to change.
- AI analysis is pending for NRSNW.